CNR1
ENSG00000118432
Target class
GPCR
Chromosome
6
Approved drugs
4
Clinical candidates (approved and in development)
13
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- CNR1
- Gene name
- Cannabinoid receptor 1
- Gene symbol
- CNR1
- Previous gene symbols
- CNR
- Protein name
- Cannabinoid receptor 1 (CB-R) (CB1) (CANN6)
- CB1K5
- CB-R
- CB1
- CANN6
- CB1A
- Gene biotype
- Protein coding
- Gene family
- Cannabinoid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 47
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 33.9
- Tissue specificity (Gini)
- 0.516
- Tissue specificity (tau)
- 0.738
- KEGG gene identifiers
- hsa:1268
- Protein interaction confidence
- 0.854975
- Protein interaction partners
- 40
- R-HSA-373076
- R-HSA-418594
- End position
- 88167364
- Start position
- 88139863
- Chromosome
- 6
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Membrane raft . Mitochondrion outer membrane . Cell projection, axon . Presynapse . Note=Unexpectedly, in the mitochondria, the C-terminus is located in the mitochondrial intermembrane space, a compartment topologically considered as extracellular. In canonical seven-transmembrane G-protein coupled receptors, the C-terminus is cytosolic (By similarity). Found on presynaptic axon terminals in some GABAergic neurons in the somatosensory cortex (By similarity). .
- Plasma membrane
- PubMed 21895628
- PubMed 27768894
- PubMed 27851727
- Tissue specificity (tau)
- 0.737563
- Expression inequality (Gini)
- 0.516383
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 33.9
- Brain - Cerebellum
- 29.4
- Pituitary
- 29.33
- Cells - Cultured fibroblasts
- 26.92
- Adipose - Subcutaneous
- 26.04
Expression in transcripts per million
- Brain - Cerebellar Hemisphere33.9
- Brain - Cerebellum29.4
- Pituitary29.33
- Cells - Cultured fibroblasts26.92
- Adipose - Subcutaneous26.04
- Adipose - Visceral (Omentum)26.04
- Fallopian Tube25.23
- Artery - Tibial23.72
- Breast - Mammary Tissue18.99
- Brain - Anterior cingulate cortex (BA24)18.79
- Colon - Sigmoid17.51
- Brain - Frontal Cortex (BA9)16.89
- Small Intestine - Terminal Ileum13.88
- Brain - Cortex13.09
- Brain - Caudate (basal ganglia)12.87
- Brain - Putamen (basal ganglia)11.97
- Brain - Hippocampus10.92
- Brain - Amygdala9.36
- Esophagus - Gastroesophageal Junction9.31
- Nerve - Tibial9.31
- Brain - Hypothalamus9.15
- Colon - Transverse8.72
- Esophagus - Muscularis7.63
- Brain - Nucleus accumbens (basal ganglia)7.46
- Uterus7.38
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007188
- GO:0038171
- GO:0005886
- GO:0045121
- GO:0004949
- GO:0005515
- GO:0042802
catalepsy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: catalepsy
- nervous system
- cardiovascular
PubMed 28216264headache
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: headache
- nervous system
- cardiovascular
PubMed 28216264hallucinations
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: hallucinations
- nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- cardiovascular
PubMed 28216264nervousness
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: nervousness
- nervous system
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased heart rate
- nervous system
- cardiovascular
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- cardiovascular
PubMed 28216264dysphoria
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: dysphoria
- nervous system
- cardiovascular
PubMed 28216264drowsiness
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drowsiness
- nervous system
- cardiovascular
PubMed 28216264decreased eating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased eating
- nervous system
- cardiovascular
PubMed 28216264dizziness
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: dizziness
- nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- nervous system
- cardiovascular
PubMed 28216264increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- nervous system
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- nervous system
- cardiovascular
PubMed 28216264increased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased eating
- nervous system
- cardiovascular
PubMed 28216264
dysphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dysphoria
Biological samples
- central nervous system
PubMed 23197038anxiety
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: anxiety
Biological samples
- central nervous system
PubMed 23197038poor concentration
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: poor concentration
Biological samples
- central nervous system
PubMed 23197038depression
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: depression
Biological samples
- central nervous system
PubMed 23197038memory impairment
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: memory impairment
Biological samples
- central nervous system
PubMed 23197038euphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: euphoria
Biological samples
- central nervous system
PubMed 23197038increased weight loss
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased weight loss
Biological samples
- central nervous system
PubMed 23197038hypothermia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hypothermia
Biological samples
- central nervous system
PubMed 23197038emesis
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: emesis
Biological samples
- central nervous system
PubMed 23197038analgesia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: analgesia
Biological samples
- central nervous system
PubMed 23197038
Related records
Trials (871)
- A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
- A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
- A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
- A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
- A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
- A Clinical Trial on the Antipsychotic Properties of Cannabidiol
- A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
- A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy
- A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
- A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
- A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
- A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
- A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
- A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients
- A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers
- A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions
- A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
- A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
- A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
Drugs (13)
- AZD2207 Cannabinoid CB1 receptor antagonist
- Cannabidiol Cannabinoid CB1 receptor negative allosteric modulator
- Drinabant Cannabinoid CB1 receptor antagonist
- Dronabinol Cannabinoid CB1 receptor agonist
- Ibipinabant Cannabinoid CB1 receptor antagonist
- Nabilone Cannabinoid CB1 receptor agonist
- Nimacimab Cannabinoid CB1 receptor negative allosteric modulator
- Nonabine Cannabinoid CB1 receptor agonist
- Otenabant Cannabinoid CB1 receptor antagonist
- Rimonabant Cannabinoid CB1 receptor antagonist
- SAD448 Cannabinoid CB1 receptor agonist
- Surinabant Cannabinoid CB1 receptor antagonist
- Taranabant Cannabinoid CB1 receptor inverse agonist